Compare SPRY & PFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPRY | PFLT |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | 163 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 833.1M | 805.6M |
| IPO Year | 2020 | 2010 |
| Metric | SPRY | PFLT |
|---|---|---|
| Price | $8.41 | $8.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $40.00 | $10.67 |
| AVG Volume (30 Days) | ★ 1.5M | 968.5K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 14.98% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $84,278,000.00 | N/A |
| Revenue This Year | $90.76 | $8.16 |
| Revenue Next Year | $81.70 | N/A |
| P/E Ratio | ★ N/A | $24.14 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.66 | $7.68 |
| 52 Week High | $18.63 | $10.88 |
| Indicator | SPRY | PFLT |
|---|---|---|
| Relative Strength Index (RSI) | 48.60 | 55.08 |
| Support Level | $8.33 | $7.92 |
| Resistance Level | $8.70 | $9.46 |
| Average True Range (ATR) | 0.56 | 0.23 |
| MACD | 0.08 | 0.06 |
| Stochastic Oscillator | 63.48 | 95.92 |
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate both current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generates revenue in the form of interest income on the debt securities and dividends.